These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35994200)

  • 41. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.
    Suilik HA; Jaber F; Abuelazm M; Ramadan A; Elzeftawy MA; Elrosasy A; Youssef RA; Abdelazeem B; Hashash JG; Farraye FA; Ghoz H
    Inflamm Res; 2024 Feb; 73(2):183-198. PubMed ID: 38153524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis.
    Sandlow S; Rai P; Shum A; Chen H; Arnold J; Jangi S
    ACG Case Rep J; 2023 Feb; 10(2):e00929. PubMed ID: 36788790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Judicious Use of Ozanimod for Ulcerative Colitis and Multiple Sclerosis.
    Jhon GF; Forster EM
    ACG Case Rep J; 2024 Apr; 11(4):e01332. PubMed ID: 38628167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ozanimod (Zeposia) for ulcerative colitis.
    Med Lett Drugs Ther; 2021 Sep; 63(1633):147-151. PubMed ID: 34550962
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes.
    Cohen NA; Weber CR; Cheng JX; Choi D; Garcia NM; Choi NK; Rubin DT
    J Crohns Colitis; 2024 Apr; 18(4):638-641. PubMed ID: 37879626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methotrexate for induction of remission in ulcerative colitis.
    Chande N; Wang Y; MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006618. PubMed ID: 25162749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2012 Nov; 11():CD004118. PubMed ID: 23152224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
    Wang J; Goren I; Yang B; Lin S; Li J; Elias M; Fiocchi C; Rieder F
    Aliment Pharmacol Ther; 2022 Feb; 55(3):277-291. PubMed ID: 34932238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
    N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center.
    Cohen NA; Choi D; Choden T; Cleveland NK; Cohen RD; Rubin DT
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2407-2409.e2. PubMed ID: 35381385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Probiotics for induction of remission in ulcerative colitis.
    Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Matsuoka K; Watanabe M; Ohmori T; Nakajima K; Ishida T; Ishiguro Y; Kanke K; Kobayashi K; Hirai F; Watanabe K; Mizusawa H; Kishida S; Miura Y; Ohta A; Kajioka T; Hibi T;
    Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):648-657. PubMed ID: 35366419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.